Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 4 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| State of the Industry | 9 | 12 |
| Introduction | 9 | 1 |
| The Rising Costs of Drug Development | 10 | 2 |
| Drug Attrition | 12 | 2 |
| Patent Expiries | 14 | 1 |
| Regulatory Hurdles | 15 | 1 |
| The Fourth Hurdle: Reimbursement | 16 | 1 |
| Innovation in the Drug Development Paradigm | 16 | 1 |
| The Critical Path Initiative | 16 | 2 |
| The Innovative Medicines Initiative | 18 | 1 |
| Improving Drug Development | 19 | 1 |
| 2012 and Beyond | 20 | 1 |
| Collaboration in the Precompetitive Space | 21 | 17 |
| Defining Precompetitive Research | 21 | 2 |
| Building Successful Consortia | 23 | 1 |
| Choosing the Research Topic | 23 | 1 |
| The Set-Up Phase | 23 | 1 |
| Project Management | 24 | 1 |
| Measuring Success | 25 | 1 |
| Case Study of a Successful Private Public Partnership: The Alzheimer s Disease Neuroimaging Initiative | 26 | 1 |
| Qualification of Biomarkers of Efficacy or Safety | 26 | 3 |
| Case Study: Biomarkers of Kidney Injury | 29 | 2 |
| Case Study: The Biomarkers Consortium | 31 | 1 |
| Open Innovation Platforms | 32 | 1 |
| Case Study: OpenPHACTS | 33 | 1 |
| Case Study: Sage Bionetworks | 34 | 1 |
| Data Standards | 35 | 1 |
| BioSharing: Standard Cooperating Procedures | 35 | 1 |
| Clinical Data Standards | 36 | 1 |
| Data Standards and the FDA | 36 | 1 |
| Conclusions | 37 | 1 |
| Improving Drug Development Efficiency | 38 | 10 |
| Modeling and Simulation | 38 | 1 |
| Modeling and Simulation: A View from the Regulators | 39 | 1 |
| Model Qualification | 40 | 1 |
| Modeling and Simulation Expertise and Consultancy | 40 | 1 |
| Innovative Approaches to Clinical Trials | 41 | 1 |
| Adaptive Clinical Trials | 42 | 2 |
| Case Study: The I-SPY 2 Trial | 44 | 1 |
| Exploratory Clinical Trials | 45 | 1 |
| Microdosing | 45 | 1 |
| Studies of Drug Metabolism in Early Development | 46 | 1 |
| Engaging Stakeholders | 46 | 1 |
| Patients | 46 | 1 |
| Regulators | 47 | 1 |
| Payers | 47 | 1 |
| Conclusions | 47 | 1 |
| Business Models | 48 | 12 |
| Introduction | 48 | 1 |
| R&D Reorganization | 48 | 1 |
| Mimicking the Biotech Environment | 48 | 1 |
| The Fully Integrated Pharmaceutical Network Model | 49 | 1 |
| Open Innovation | 50 | 1 |
| Case Study: An Open Innovation Incubator | 51 | 1 |
| Case Study: Open Innovation Drug Discovery at Eli Lilly | 52 | 1 |
| Funding for External Innovation | 53 | 1 |
| Collaborative Commercialization | 54 | 1 |
| Academic Partnerships and Translational Medicine | 55 | 2 |
| Translational Science in the US | 57 | 1 |
| Case study: Medical Research Council/AstraZeneca | 58 | 1 |
| Conclusions | 59 | 1 |
| Appendix | 60 | 7 |
| Abbreviations | 60 | 1 |
| Methodology | 61 | 2 |
| Primary Research | 61 | 1 |
| Secondary Research | 62 | 1 |
| References | 62 | 4 |
| Contact Us | 66 | 1 |
| Disclaimer | 66 | 1 |